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The NO/ONOO(-) cycle is primarily a local complex, 
biochemical, vicious cycle mechanism based on well-
established processes (1). The cycle is thought to be the 
possible cause of different diseases when localized in 
various body tissues. The most extensively documented 
of these is heart failure, where the impact of the cycle in 
the myocardium causes the vast changes that occur in 
heart failure (1). The main question being raised here is 
whether the impact of the NO/ONOO(-) cycle in the 
trabecular meshwork, and subsequently in the retinal 
ganglion, is the cause of open-angle glaucoma. An 
important notion here is that the high intraocular 
pressure (IOP) resulting from changes in the trabecular 
meshwork produces physical trauma and elevated NMDA  
activity; there is consequent initiation of the NO/ONOO(-
) cycle in the retinal ganglion, leading to retinal ganglion 
cell (RGC) degeneration. A second question relates to 
whether the high IOP in closed-angle glaucoma, and also 
highly variable but normal range IOP in other types of 
glaucoma, may both act on the retinal ganglion via 
physical trauma and the NO/ONOO(-) cycle to produce 
RGC degeneration. 
The NO/ONOO(-) cycle has 12 different elements which 
are increased by the cycle in the impacted tissue (1). 
These elements include: nitric oxide (NO), superoxide, 
peroxynitrite, oxidative stress, NF-B, inflammatory 
cytokines, iNOS induction, mitochondrial dysfunction, 
excitotoxicity including excessive NMDA activity, 
intracellular calcium, elevated activity of several of the 
TRP receptors, and tetrahydrobiopterin depletion. All 
except the last two of these have been examined and 
shown at increased levels in the retinal ganglion in 
glaucoma. Most of these elements have been explored 
and also found at elevated levels in the trabecular 
meshwork in open-angle glaucoma. 
Let’s consider the trabecular meshwork first. One of the 
stressors that produces the trabecular remodeling found 
in open-angle glaucoma is H(2)O(2) treatment. Li et al. (2) 
found that H(2)O(2) treatment of the trabecular 
meshwork produced chronic elevation of oxidative 
stress, as well as that of NO, iNOS, NF-B, inflammatory 
cytokines and mitochondrial dysfunction—six elements 
of the NO/ONOO(-) cycle. Other studies have implicated 
both peroxynitrite and intracellular calcium, in addition 
to the aforementioned six cycle elements, in glaucoma-
associated trabecular meshwork changes. Still other 
changes linked to the NO/ONOO(-) cycle in heart failure 
(1)—matrix metalloproteinase (MMP), calpain and 
endothelin-1 elevation—are also implicated in the 
trabecular meshwork changes in open-angle glaucoma. 
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The finding that the oxidant H(2)O(2) treatment 
generates chronic changes, including oxidative stress, 
strongly suggests a vicious cycle in the generation of the 
trabecular meshwork changes. The finding of elevation of 
so many NO/ONOO(-) cycle elements in this trabecular 
meshwork process strongly suggests that the 
NO/ONOO(-) cycle is the vicious cycle involved. MMP 
elevation and many other changes found in the tissue 
remodeling in heart failure can all be causally linked to 
NO/ONOO(-) cycle elements (1), suggesting that 
remodeling of the trabecular meshwork in glaucoma may 
be similarly explained. 
Physical trauma has been shown to produce excessive 
activity of the NMDA receptors in the brain and spinal 
cord, subsequently leading to traumatic brain injury and 
spinal cord injury. In various publications the author has 
discussed how excessive NMDA activity may be involved 
in initiating cases of diseases apparently caused by the 
NO/ONOO(-) cycle. The role of excessive NMDA activity 
in causing RGC degeneration in glaucoma has been 
reviewed by Seki and Lipton (3). It is reasonable, 
therefore, that high or highly variable IOP creates 
physical trauma on the RGCs in the region where the 
retinal ganglion leaves the eye, thereby producing 
excessive NMDA activity via several possible 
mechanisms, as discussed earlier (3). The excessive 
NMDA activity may act on the RGCs to initiate the 
NO/ONOO(-) cycle in the retinal ganglion, causing 
glaucoma. 
Most of the NO/ONOO(-) cycle elements have been 
studied and shown to be raised in the retinal ganglion in 
glaucoma, namely: superoxide, nitric oxide, 
peroxynitrite, oxidative stress, NF-B, inflammatory 
cytokines, iNOS, mitochondrial dysfunction, NMDA 
activity and intracellular calcium (4,5) with most of these 
having causal roles in RGC changes and apoptosis. This 
pattern of evidence makes it highly likely that the 
NO/ONOO(-) cycle has a central causal role in the retinal 
ganglion in glaucoma. Because the NO/ONOO(-) cycle 
produces mitochondrial changes that can lead to 
apoptosis (1), its apparent role here makes mechanistic 
sense. 
It is the author’s view that treatments raising Nrf2 
activity are likely to be promising treatments for 
glaucoma because of the role of Nrf2 in lowering 
multiple NO/ONOO(-) cycle elements. This position is 
also suggested by Miyamoto et al.’s recent study of 
quercetin acting by raising Nrf2 in glaucoma treatment. 
In summary, the local impact of the NO/ONOO(-) cycle in 
the trabecular meshwork may lead to remodeling of that 
meshwork and consequent high  IOP. Other mechanisms 
in closed-angle and other types of glaucoma can also 
lead to high or variable normal range IOP, both of which 
act via physical trauma on RGC to elevate NMDA activity 
and initiate the NO/ONOO(-) cycle in RGC. The 
NO/ONOO(-) cycle in the RGC produces both apoptotic 
cell death and other changes, including tissue 
remodeling. Agents that raise Nrf2 may thus be expected 
to be effective in glaucoma treatment however more 
studies are required.  
On behalf of editorial board, it is our pleasure to 
announce that PubMed central has accepted the journal, 
“Med Hypothesis Discov Innov Ophthalmol” for inclusion 
in its database. This means that the articles published in 
our journal will now be available to search using 
PubMed, which most practitioners use to access 
academic resources. We have seen not only a pleasing 
increase in unsolicited submissions to the journal but 
also increased readership over these last few months. In 
this issue most articles are related to glaucoma and we 
hope you enjoyed reading the Journal content. 
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